| |
|
 |
|
MODERN RHEUMATOLOGY Vol.13 No.4
>MR13-4
|
Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyositis and dermatomyositis
|
|
| Masako Hara1 , Masao Kinoshita2, Eizo Saito2, Hiroshi Hashimoto3, Nobuyuki Miyasaka4, Tadashi Yoshida5, Yoichi Ichikawa6, Takao Koike7, Yukinobu Ichikawa8, Jun Okada9 and Sadao Kashiwazaki1 |
(1) IVIG Study group, Institute of Rheumatology, Tokyo Womens Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo, 162-0054, Japan
(2) IVIG Study Group, Toho University, Tokyo, Japan
(3) IVIG Study Group, Juntendo University, Tokyo, Japan
(4) IVIG Study Group, Tokyo Medical and Dental University, Tokyo, Japan
(5) IVIG Study Group, Keio University, Tokyo, Japan
(6) IVIG Study Group, St. Marianna Medical University, Kawasaki, Japan
(7) IVIG Study Group, Hokkaido University, Sapporo, Japan
(8) IVIG Study Group, Tokai University, Isehara, Japan
(9) IVIG Study Group, Kitasato University, Sagamihara, Japan |
| |
| Received: 26 September 2002 Accepted: 06 February 2003 |
| |
Full Text
> Click Here （member's only） |
| |
| Abstract |
| High-dose intravenous immunoglobulin (IVIG) therapy has been effective in treating many autoimmune and systemic inflammatory diseases. In the present prospective study, we evaluated the efficacy of IVIG for patients with polymyositis (PM) and dermatomyositis (DM) refractory to treatment with high-dose corticosteroids. PM/DM was defined as steroid-resistant when the muscle strength of a patient did not improve despite the administration of more than 50mg prednisolone per day for more than 4 weeks. A total of 12 patients with biopsy-proven, steroid-resistant PM/DM received one infusion of polyethylene glycol-treated human IgG at a dose of 0.4g per kg per day for five successive days. Three of the patients received a second infusion. All patients were followed for up to 3 months after the infusion. Finally, 8 patients (6 PM and 2 DM; 5 men and 3 women) aged 29?67 years (mean 48 years) were analyzed. Their clinical response was assessed by changes in (a) subjective signs, i.e., fatigue (visual analog scale, VAS), muscle pain (VAS), activities of daily living (ADL), (b) objective signs, i.e., manual muscle strength (MMT) and serum level of creatine kinase (CK). At 12 weeks after the infusion, the patients showed significant improvement in their scores of muscle strength (from a mean of 67.0 to 81.0) and their ADL scores (from a mean of 27.1 to 39.1). The mean serum CK level decreased significantly from 1287.4 to 612.6IU/l. In addition, the mean VAS of fatigue decreased significantly from 5.5 to 1.3cm. The physicians assessment showed that 87.5% of patients had improved. The average reduced dose of prednisolone was 47.1mg/day at 12 weeks after infusion in 7 patients who exhibited improvement. Adverse effects, i.e., asymptomatic myocardial infarction and increased blood urea nitrogen (BUN), were noted with two of the 15 infusion (13%). Overall, IVIG was found to be safe and effective for refractory PM and DM. |
| |
| Key words |
| Dermatomyositis (DM) - High-dose intravenous immunoglobulin (IVIG) - Polymyositis (PM) |
|
| |
| 一覧に戻る |
|
|
